Covered recipient · General Payments record
MARC BERNSTEIN
Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$2,129.17
151 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $2,096.62 | 148 |
| Education | $32.55 | 3 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Medtronic, Inc. | $269.99 | 23 |
| Janssen Pharmaceuticals, Inc | $233.54 | 17 |
| Novartis Pharmaceuticals Corporation | $208.91 | 16 |
| Philips Electronics North America Corporation | $194.72 | 3 |
| Amgen Inc. | $175.39 | 16 |
| PFIZER INC. | $152.91 | 15 |
| Merck Sharp & Dohme LLC | $134.88 | 12 |
| Bayer HealthCare Pharmaceuticals Inc. | $133.04 | 9 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $73.90 | 5 |
| Amarin Pharma Inc. | $60.37 | 4 |
| E.R. Squibb & Sons, L.L.C. | $60.16 | 4 |
| iRhythm Technologies, Inc. | $59.69 | 3 |
| Actelion Pharmaceuticals US, Inc. | $56.72 | 3 |
| Esperion Therapeutics, Inc. | $54.92 | 4 |
| Lilly USA, LLC | $43.04 | 3 |
| AstraZeneca Pharmaceuticals LP | $39.08 | 3 |
| Kowa Pharmaceuticals America, Inc. | $35.75 | 2 |
| SANOFI-AVENTIS U.S. LLC | $28.64 | 2 |
| Amryt Pharma Holdings Ltd | $28.40 | 2 |
| Regeneron Healthcare Solutions, Inc. | $24.59 | 1 |
| GlaxoSmithKline, LLC. | $18.01 | 1 |
| Boston Scientific Corporation | $17.50 | 1 |
| Novo Nordisk Inc | $12.98 | 1 |
| ConvaTec Inc. | $12.04 | 1 |
Page 4 of 4; records 151–151 of 151 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARC BERNSTEIN
NPI 1851333587 · CMS profile ID 83695
Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease
SLIDELL, LA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 4; records 151–151 of 151 matching records. This page contains 1 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1851333587?year=2022&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARC BERNSTEIN, NPI 1851333587, CMS profile ID 83695. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–151 of 151 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851333587?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). MARC BERNSTEIN, NPI 1851333587, CMS profile ID 83695. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–151 of 151 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851333587?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- MARC BERNSTEIN, NPI 1851333587, CMS profile ID 83695, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–151 of 151 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1851333587?year=2022&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
151 matching records · $2,129.17 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–151 of 151.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Esperion Therapeutics, Inc. | $14.57 | 01/04/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947243975 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $428,785.67 | 125 |
| PY2024 | Recipient | $45,424.00 | 1 |
| PY2024 | Principal investigator | $296,572.58 | 29 |
| PY2023 | Principal investigator | $282,073.94 | 36 |
| PY2022 | Principal investigator | $159,913.35 | 25 |
| PY2021 | Principal investigator | $287,609.81 | 133 |
| PY2020 | Principal investigator | $319,223.54 | 241 |
| PY2019 | Principal investigator | $349,949.75 | 55 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
125 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Amgen Inc. | $1,878.00 | 12/24/2025 | Non-covered Recipient Entity DRS ITELD BERNSTEIN & ASSOC DBA LA HEART CTR | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246640875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 12/15/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628833 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 12/15/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,630.00 | 12/15/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628837 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 12/15/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628839 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,573.00 | 12/12/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224758 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220628681 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628829 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 12/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628831 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 11/26/2025 | Non-covered Recipient Entity Louisiana Heart Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220792515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 11/19/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,097.00 | 11/19/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 11/19/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628827 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,380.00 | 11/19/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224751 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 11/11/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220994421 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,181.00 | 11/07/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224781 |
| Principal investigator 1 | Janssen Research & Development, LLC | $864.00 | 11/03/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224852 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220628677 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220628679 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628819 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 11/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628821 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.74 | 10/27/2025 | Non-covered Recipient Entity Louisiana Heart Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220628683 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 10/27/2025 | Non-covered Recipient Entity Louisiana Heart Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220628685 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,276.00 | 10/20/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628815 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 10/20/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 10/02/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628809 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,423.00 | 10/02/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628811 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 10/02/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628813 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220628669 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 10/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220628671 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 10/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220628673 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 10/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220628675 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628805 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 10/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628807 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $319.68 | 09/24/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628797 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 09/24/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628799 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.61 | 09/24/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628801 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.64 | 09/24/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628803 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,783.00 | 09/19/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224765 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $4,000.00 | 09/18/2025 | Non-covered Recipient Entity ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190309482 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 09/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628773 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,352.00 | 08/25/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224792 |
| Principal investigator 1 | Amgen Inc. | $7,500.00 | 08/23/2025 | Non-covered Recipient Entity DRS ITELD BERNSTEIN & ASSOC DBA LA HEART CTR | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246640883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $270.00 | 08/20/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628781 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 08/20/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220994419 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,380.00 | 08/13/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,758.00 | 08/13/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,720.00 | 08/13/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628785 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,380.00 | 08/13/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,758.00 | 08/13/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,720.00 | 08/13/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,423.00 | 08/13/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628793 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628767 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 08/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628769 |
| Principal investigator 1 | Amgen Inc. | $1,592.24 | 07/28/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER - HAMMOND | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246643645 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 07/28/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628795 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,828.00 | 07/25/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,310.00 | 07/25/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,660.00 | 07/25/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628765 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,837.00 | 07/23/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224834 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 07/03/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220994417 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628775 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 07/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628777 |
| Principal investigator 1 | Amgen Inc. | $5,118.98 | 06/24/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER - HAMMOND | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) | No dispute reported | 06/30/2026 | 1246643656 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $93.28 | 06/24/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628759 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,822.00 | 06/23/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224811 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,601.00 | 06/20/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224735 |
| Principal investigator 1 | Amgen Inc. | $341.00 | 06/05/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246643659 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,828.00 | 06/04/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 06/04/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628737 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,828.00 | 06/04/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628739 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,097.00 | 06/04/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,179.00 | 06/04/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628743 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,310.00 | 06/04/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628745 |
| Principal investigator 1 | Amgen Inc. | $6,121.00 | 06/03/2025 | Non-covered Recipient Entity DRS ITELD BERNSTEIN & ASSOC DBA LA HEART CTR | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | No dispute reported | 06/30/2026 | 1246640881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628731 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 06/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $159.84 | 05/27/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628751 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 05/27/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.96 | 05/27/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628755 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.76 | 05/27/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628757 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,719.00 | 05/21/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224772 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628727 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 05/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628729 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $3,338.48 | 04/30/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220994415 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,660.00 | 04/25/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628725 |
| Principal investigator 1 | Amgen Inc. | $18,757.80 | 04/24/2025 | Non-covered Recipient Entity DRS ITELD BERNSTEIN & ASSOC DBA LA HEART CTR | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246640877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $299.70 | 04/23/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.55 | 04/23/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628749 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,538.00 | 04/23/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224827 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 03/25/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628717 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.82 | 03/25/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628719 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,124.00 | 03/21/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224744 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,828.00 | 03/19/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628703 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $206.00 | 03/19/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,310.00 | 03/19/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628707 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $5,007.72 | 03/13/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220994413 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628697 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 03/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628699 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $6,284.50 | 02/27/2025 | Non-covered Recipient Entity ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190303511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $239.76 | 02/25/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628709 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $328.50 | 02/25/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628711 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.61 | 02/25/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628713 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.58 | 02/25/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628715 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,224.80 | 02/20/2025 | Non-covered Recipient Entity ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190303517 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,399.00 | 02/19/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224803 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $30,936.46 | 02/03/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190302099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 02/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628693 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 02/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628695 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $210.00 | 01/31/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628701 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $9,880.20 | 01/30/2025 | Non-covered Recipient Entity ITELD BERNSTEIN ASSOCIATES DBA LOUISIANA HEART CENTER | Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) | No dispute reported | 06/30/2026 | 1190303509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,179.00 | 01/22/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628687 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,963.00 | 01/22/2025 | Non-covered Recipient Entity Louisiana Heart Ctr | A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | No dispute reported | 06/30/2026 | 1175224843 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,708.47 | 01/15/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER RESEARCH | A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease | No dispute reported | 06/30/2026 | 1190309218 |
| Principal investigator 1 | Eli Lilly and Company | $2,223.09 | 01/09/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187884506 |
| Principal investigator 1 | Amgen Inc. | $433.04 | 01/08/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER | OCEAN(a)-Outcomes Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction Outcomes trial | No dispute reported | 06/30/2026 | 1246643667 |
| Principal investigator 1 | Eli Lilly and Company | $113,460.00 | 01/07/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | No dispute reported | 06/30/2026 | 1187884182 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $33,904.65 | 01/06/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER RESEARCH | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) | No dispute reported | 06/30/2026 | 1190309216 |
| Principal investigator 1 | Amgen Inc. | $10,534.46 | 01/02/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER - HAMMOND | A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) | No dispute reported | 06/30/2026 | 1246643649 |
| Principal investigator 1 | Amgen Inc. | $13,906.20 | 01/02/2025 | Non-covered Recipient Entity LOUISIANA HEART CENTER | A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke | No dispute reported | 06/30/2026 | 1246643663 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628689 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity Louisiana Heart Center | EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) | No dispute reported | 06/30/2026 | 1220628691 |